The Clinical Efficacy and Safety of Neratinib in Combination with Capecitabine for the Treatment of Adult Patients with Advanced or Metastatic HER2-Positive Breast Cancer

Human epidermal growth factor receptor 2 (HER2) positive cancers account for 15–20% of all breast tumors. Several drugs have been approved in the metastatic setting, including monoclonal antibodies, tyrosine kinase inhibitors (TKI) and, more recently, antibody-drug conjugates. Neratinib is a pan-HER...

Descripción completa

Detalles Bibliográficos
Autores principales: Chilà, Giovanna, Guarini, Vincenzo, Galizia, Danilo, Geuna, Elena, Montemurro, Filippo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8232377/
https://www.ncbi.nlm.nih.gov/pubmed/34188449
http://dx.doi.org/10.2147/DDDT.S281599

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8232377/
https://www.ncbi.nlm.nih.gov/pubmed/34188449
http://dx.doi.org/10.2147/DDDT.S281599

Ejemplares similares